E71.520 Insurance Policy Changes

ICD-10 E71.520 is officially defined as "Childhood cerebral X-linked adrenoleukodystrophy." code E71.520 is referenced in 4 tracked payer policy changes from Independence Blue Cross and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code E71.520 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Independence Blue Cross · Identified Oct 1, 2026Medium impact
08.01.92, Elivaldogene Autotemcel [eli-cel (Skysona®)]
Independence Blue Cross reissued Policy 08.01.92 on September 30, 2026 (most recent revision) to reaffirm its continuing coverage position for elivaldogene autotemcel (Skysona®) for treating cerebral adrenoleukodystrophy (CALD) in eligible boys ages 4-17. This is a reissue with no substantive changes to coverage criteria, requiring documentation of genetic confirmation, elevated very-long-chain fatty acids, early active CALD markers, adequate organ function, and negative infectious disease screening. Billing teams must ensure claims use the correct HCPCS codes and include all required clinical documentation to support medical necessity.
Aetna · Identified Aug 19, 2026Medium impact
Invasive Prenatal Diagnosis of Genetic Diseases (CPB 0358, reviewed 2026-05-22)
Aetna's Clinical Policy Bulletin 0358 considers invasive prenatal diagnosis by chorionic villus sampling (CVS), genetic amniocentesis, and percutaneous umbilical blood sampling (PUBS, cordocentesis) medically necessary for diagnosing fetal chromosomal abnormalities. Preimplantation genetic testing for monogenic disorders (PGT-M) is medically necessary only when the listed criteria are met, including a known carrier parent for the specific indication, a specific identified mutation, and a procedure that eliminates the need for later invasive prenatal diagnosis. PGT-A, PGT-M for fetal chromosomal abnormalities, PGT-M to determine HLA status for stem cell donation, multigene panels at PGT-M testing, and invasive screening or PGT for a variant of uncertain significance are considered experimental, investigational, or unproven, as are the Igenomix PGT-M, PGT-SR, Smart PGT-A and Smart PGT-A Plus tests, the IriSight Prenatal Analysis, and the Natera Spectrum PGT-M test.
Aetna · Identified Aug 13, 2026Medium impact
Pharmacogenetic and Pharmacodynamic Testing (CPB 0715, reviewed 2025-12-03)
Aetna Clinical Policy Bulletin 0715 (reviewed 2025-12-03) sets coverage rules for pharmacogenetic and pharmacodynamic testing, listing the tests it considers medically necessary for specific drugs and indications, including EGFR, BRAF, KRAS, BRCA, ALK, DPYD, CYP2C19, CYP2D6, HLA-B*1502 and HLA-B*5701 testing. It considers multi-gene pharmacogenetics panels and many other listed tests experimental, investigational or unproven, and it considers several FoundationOne, Guardant360 CDx and oncoReveal panels not medically necessary for particular indications because there is no proven advantage over targeted testing for those indications. This is so check current applicability with Aetna before relying on it.
Aetna · Identified Aug 13, 2026Medium impact
Elivaldogene Autotemcel (Skysona) (CPB 1017, reviewed 2026-04-08)
This Clinical Policy Bulletin covers elivaldogene autotemcel (Skysona) for commercial medical plans and requires precertification for all Aetna participating providers and members in applicable plan designs. Aetna considers a one-time administration medically necessary for cerebral adrenoleukodystrophy (CALD) only when the member is a male aged 4 to 17 with a confirmed ABCD1 pathogenic variant and elevated very long chain fatty acids, has early active disease (Loes score 0.5 to 9 with gadolinium enhancement and a neurologic function score of 1 or less), is eligible for a hematopoietic stem cell transplant but has no HLA-matched donor, and has not received Skysona, other gene therapy, or an allogeneic transplant. The member must also meet the listed hematologic, hepatic, renal, cardiac, infection and serology criteria, and Aetna considers all other indications experimental, investigational, or unproven.

Watch E71.520

Get one email when a payer policy names E71.520, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code E71.520?

There are 4 tracked policy changes affecting code E71.520, including updates from Independence Blue Cross, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code E71.520?

Payers that have issued tracked updates for code E71.520 include: Independence Blue Cross, Aetna.

How do I get notified when code E71.520 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code E71.520. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code E71.520?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

08.01.92, Elivaldogene Autotemcel [eli-cel (Skysona®)]

Invasive Prenatal Diagnosis of Genetic Diseases (CPB 0358, reviewed 2026-05-22)

Pharmacogenetic and Pharmacodynamic Testing (CPB 0715, reviewed 2025-12-03)

Elivaldogene Autotemcel (Skysona) (CPB 1017, reviewed 2026-04-08)

What insurance policy changes affect code E71.520?

Which payers have updated policy for code E71.520?

How do I get notified when code E71.520 policy changes?

Why do payers change policies for code E71.520?